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Since the introduction of coronary angioplasly e decade and 
a half ago. the issue of recurrence of stenosis or occlusion 
within 6 months of the procedure has been a pivotal lirmting 
factor. It is clear that our understanding of the basic patho- 
physiology of restenosis is incomplete. but that the prevail- 
ing mechanism in many patients involves vessel wall injury. 
platelet and lhrombin reactivity as well as growth factors and 
a robust smooth muscle cell proliferative response. More 
than Mo.MKJ coronary engio&sty procedures were per- 
formed in the United States clone durinp. 1990: it is therefurc 
essential that we soon identify either preventive mtexres or 
effective therapies to limit restenosis. 
Over the past 2 wars we have asked many of Ihe leadinr 
basic scienti& andclinictd investigators to &icipetc in ai 
international. interdisciplinary workshop on restenosi>. Thi?, 
past year 29 investigators and their colleague, put together 
an extraordinary effort that summarizes their latert work end 
insights in this field. Together with several associates. we 
have gathered and edited their data. subjected each to close 
peer rewrw and remain confident hat in this wpplement you 
will find conalderable illuminating end important data and 
theories on restenonis. 
The wpplement is divided into four secttons. The first 
defines the topic and emphasizer clinical. angiographic and 
pathologtc abpectr. Nine repins address varied topics from 
ang~ow~py of restenosis to endothelial modulatton of ves- 
cular tone. In the second aectwn. another nine rewrts arc 
focused on dreg interventions that may limit restenosis. 
includine thrombin or platelet inhibitors and antiproliferative 
agents. ihe third &ion bnnpr an up-to-date &v oi new 
technologie\ thal have in part been designed to diminish 
myomttmal hyperplasiaorrecoil after coronary intervention. 
Several techniques such as stcntmg. laser. site-s+fic drug 
thcrepy and gene transfer are discussed. In the Ia<1 section. 
original ;Ib>ttracts that were presented es posters during the 
aork\hop ere presented. 
It ih without qccsfion that close cooperation between 
talented basic scientists and clinical researchers will be vital 
for etTecuve restenosis therapy to be developed. This sup- 
plc~~nt xpresentr a” out&‘th of such cr&stalk and ‘& 
remain very deeply indebted to the sponsors, Hoffman 
LaRoche (BaseI. SwitzerlandI. Wedtronic. Pfizer. USCI- 
CR. Bard. Glaxo. Upjohn and DVI for making this mther 
lengthy and expensive publication possible, and for our 
complete autonomy for establishing its contents. 
